Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP1A1 | P05023 | 7/20 | 0.72 |
| ▸ | ATP1B1 | P05026 | 7/20 | 0.72 |
| ▸ | ATP1A3 | P13637 | 7/20 | 0.72 |
| ▸ | ATP1B2 | P14415 | 7/20 | 0.72 |
| ▸ | ATP1A2 | P50993 | 7/20 | 0.72 |
| ▸ | ATP1B3 | P54709 | 7/20 | 0.72 |
| ▸ | FXYD2 | P54710 | 7/20 | 0.72 |
| ▸ | ATP1A4 | Q13733 | 7/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.72 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.72 |
| ▸ | AR | P10275 | 1/20 | 0.72 |
| ▸ | ZFP91 | Q96JP5 | 1/20 | 0.72 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.52 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bufogenin SCHEMBL16628192 | 1.00 | ATP1A1 (0.72) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Bufogenin SCHEMBL1652389 | 1.00 | ATP1A1 (0.72) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Bufogenin SCHEMBL4528502 | 1.00 | ATP1A1 (0.72) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Bufogenin SCHEMBL8168075 | 1.00 | ATP1A1 (0.72) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Bufogenin SCHEMBL309405 | 1.00 | ATP1A1 (0.72) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Bufogenin SCHEMBL21840080 | 0.99 | ATP1A1 (0.70) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Bufogenin SCHEMBL9098303 | 0.98 | ATP1A1 (0.69) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Bufogenin SCHEMBL10587453 | 0.97 | ATP1A1 (0.68) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Bufogenin SCHEMBL9752159 | 0.97 | ATP1A1 (0.68) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Bufogenin SCHEMBL17652299 | 0.97 | ATP1A1 (0.68) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102542-A1 | ATPASE INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NON-NEUROLOGICAL DISORDERS | HAPLO THERAPEUTICS INC. (CA) | 2026-05-21 | — | — | WO | claimed |
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| WO-2025120106-A1 | METHODS FOR ISOLATING EMBRYONIC STEM CELLS FROM AN AVIAN EMBRYO CELLS | SUPRÊME (FR) | 2025-06-12 | — | — | WO | claimed |
| EP-4567102-A1 | METHODS FOR ISOLATING EMBRYONIC STEM CELLS FROM AVIAN EMBRYONIC CELLS | Suprême (FR) | 2025-06-11 | — | — | EP | claimed |
| CN-120019812-A | Artificial toad venom composition and application thereof | 南京中医药大学 | 2025-05-20 | — | — | CN | claimed |
| CN-119970755-A | Bufogenin composition, preparation and application thereof | 宁夏医科大学 | 2025-05-13 | — | — | CN | claimed |
| CN-119688900-A | Construction method and application of fingerprint spectrum of Xinbao pill | 广东心宝药业科技有限公司 | 2025-03-25 | — | — | CN | claimed |
| WO-2025051337-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING ORAL CANCER | Afyx Development A/S (DK) | 2025-03-13 | — | — | WO | claimed |
| CN-119490952-A | In vitro induction of blastocysts and uses thereof | 广州国家实验室 | 2025-02-21 | — | — | CN | claimed |
| CN-1879850-A | Capsule with hairy vein agrimony and arenobufagin, its preparation process and quality control method | ANHUI AN TECH MEDICAL AND BIOL (CN) | 2006-12-20 | — | — | CN | claimed |
| CN-1810827-A | Anticancer prepn containing three anticancer compounds of toad or toad cake and its prepn process | CUI BIN (CN) | 2006-08-02 | — | — | CN | claimed |
| CN-1785380-A | Quality control method of Chinese medicinal preparation | GUIZHOU YIBAI PHARMACEUTICAL (CN) | 2006-06-14 | — | — | CN | claimed |
| US-20050136003-A1 | Novel chemical agents comprising a cardiotonic moiety and an imaging moiety and methods of their use | LANTHEUS MEDICAL IMAGING, INC. | 2005-06-23 | — | — | US | claimed |
| WO-2005042033-A1 | NOVEL CHEMICAL AGENTS COMPRISING A CARDIOTONIC MOIETY AND AN IMAGING MOIETY AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-05-12 | — | — | WO | claimed |
| US-6726935-B2 | SECRETED FROM VENOM GLAND OF A TOAD; FORMULATED AS OINTMENT, SUSPENSION, GEL, SPRAY, PATCH OR SOLUTION; FOR PREVENTING PREMATURE, NONCONTROLLED EJACULATION AND/OR SEXUAL HYPERSENSITIVITY | CHEIL JEDANG CORPORATION (KR) | 2004-04-27 | — | — | US | claimed |
| WO-2002014343-A1 | BUFADIENOLIDE DERIVATIVES AND USE AS IMMUNOSUPPRESSIVE, ANTIINFLAMMATORY AND ANALGESIC AGENTS | TERNESS, PETER (DE) | 2002-02-21 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050136003-A1 | Novel chemical agents comprising a cardiotonic moiety and an imaging moiety and methods of their use | TNNI3, TNNT2, TNNC1 | ATP1A1 738/4885ATP1B1 236/4885ATP1A3 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.